EpitoGenesis was awarded a Phase I Advanced Technology STTR grant from the National Institutes of Allergy and Infectious Diseases to develop a vaccine against vaginal transmission of Chlamydia trachomatis, using their proprietary Nutritive Immune-enhancing Delivery System, in collaboration with Dr. Deborah Dean at Children’s Hospital Oakland Research Institute. The grant is for two years and the monetary award is $600,000. The second year of this award will be allocated to EpitoGenesis in Connecticut.
Menu